Literature DB >> 406034

Parenteral nutritional support in children with cancer.

R M Filler, N Jaffe, J R Cassady, D G Traggis, J B Das.   

Abstract

Acute and chronic starvation is often associated with childhood cancer. Total parenteral nutrition (TPN) with 20% glucose and 3.0% amino acids, and minerals and vitamins was instituted to treat or prevent malnutrition in 41 children with cancer, ages three months to 18 years. TPN was required for anorexia, vomiting and diarrhea associated with anti-cancer therapy in 33 patients for intestinal complications or surgery in nine, and for preoperative correction of malnutrition in two. During TPN, general nutrition and appearance improved in all patients. Weight gain was noted in most. Despite gastrointestinal complications which usually require the interruption of chemotherapy and irradiation, in 21 children treatment could be continued at full dose with nutritional support by TPN. TPN was discontinued in six patients when blood cultures became positive. Sepsis was treated successfully by removal of the central venous catheter in all six and administration of antibiotics in three. No metabolic complications were noted. TPN appears to be a safe and effective means of combating the malnutrition which may occur with cancer and its therapy.

Entities:  

Mesh:

Year:  1977        PMID: 406034     DOI: 10.1002/1097-0142(197706)39:6<2665::aid-cncr2820390654>3.0.co;2-j

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  2 in total

Review 1.  [Pathogenesis and therapy of malnutrition in oncology].

Authors:  G Ollenschläger
Journal:  Z Ernahrungswiss       Date:  1982-06

2.  Does body mass index at diagnosis or weight change during therapy predict toxicity or survival in intermediate risk rhabdomyosarcoma? A report from the Children's Oncology Group Soft Tissue Sarcoma Committee.

Authors:  Megan E Burke; Elizabeth R Lyden; Jane L Meza; Elena J Ladas; Roshni Dasgupta; Ellen A Wiegner; Carola A S Arndt
Journal:  Pediatr Blood Cancer       Date:  2013-01-17       Impact factor: 3.167

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.